Biotron Ltd (AU:BIT) — Market Cap & Net Worth
Market Cap & Net Worth: Biotron Ltd (BIT)
Biotron Ltd (AU:BIT) has a market capitalization of $3.82 Million (AU$5.40 Million) as of August 5, 2026. Listed on the AU stock exchange, this Australia-based company holds position #29042 globally and #1597 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biotron Ltd's stock price AU$0.00 by its total outstanding shares 2701871644 (2.70 Billion). See Biotron Ltd capex to cash flow ratio to understand how much of operating cash flow is reinvested back into capital assets.
Biotron Ltd Market Cap History: 2015 to 2026
Biotron Ltd's market capitalization history from 2015 to 2026. Data shows change from $80.10 Million to $3.82 Million (-24.96% CAGR).
Biotron Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biotron Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.16x
Biotron Ltd's market cap is 3.16 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $62.51 Million | $1.55 Million | -$3.00 Million | 40.38x | N/A |
| 2017 | $48.75 Million | $1.66 Million | -$3.09 Million | 29.38x | N/A |
| 2018 | $212.97 Million | $1.62 Million | -$1.59 Million | 131.25x | N/A |
| 2019 | $96.35 Million | $1.07 Million | -$1.61 Million | 89.81x | N/A |
| 2020 | $144.34 Million | $803.03K | -$3.58 Million | 179.74x | N/A |
| 2021 | $179.51 Million | $1.46 Million | -$3.19 Million | 122.79x | N/A |
| 2022 | $51.62 Million | $1.56 Million | -$2.78 Million | 33.12x | N/A |
| 2023 | $185.44 Million | $1.43 Million | -$3.49 Million | 129.56x | N/A |
| 2024 | $34.41 Million | $1.65 Million | -$3.44 Million | 20.92x | N/A |
| 2025 | $5.74 Million | $1.81 Million | -$318.57K | 3.16x | N/A |
Competitor Companies of BIT by Market Capitalization
Companies near Biotron Ltd in the global market cap rankings as of August 5, 2026.
Key companies related to Biotron Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #427 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #544 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #569 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $478.71 |
| #427 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $760.66 |
| #544 | Argen-X | BR:ARGX | $49.55 Billion | €728.00 |
| #569 | UCB SA | BR:UCB | $47.34 Billion | €223.30 |
Biotron Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Biotron Ltd's market cap moved from $80.10 Million to $ 3.82 Million, with a yearly change of -24.96%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$3.82 Million | -33.33% |
| 2025 | AU$5.74 Million | -83.33% |
| 2024 | AU$34.41 Million | -81.44% |
| 2023 | AU$185.44 Million | +259.26% |
| 2022 | AU$51.62 Million | -71.25% |
| 2021 | AU$179.51 Million | +24.37% |
| 2020 | AU$144.34 Million | +49.80% |
| 2019 | AU$96.35 Million | -54.76% |
| 2018 | AU$212.97 Million | +336.86% |
| 2017 | AU$48.75 Million | -22.02% |
| 2016 | AU$62.51 Million | -21.96% |
| 2015 | AU$80.10 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 5th, 2026 the market cap of Biotron Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.82 Million USD |
| MoneyControl | $3.82 Million USD |
| MarketWatch | $3.82 Million USD |
| marketcap.company | $3.82 Million USD |
| Reuters | $3.82 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Biotron Ltd
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225 for the treatment of SARS-CoV-2, HIV-1, hepatitis C virus, hepatitis B virus (HBV), influenza, and dengue virus infections. The company was incorporated in 1999 and is based in Sydney, Australia.